Publication Name	World Journal of Clinical Oncology
Manuscript ID	14825
Country	United States

Received	2014-10-27 08:34
Peer-Review Started	2014-10-28 08:12
First Decision by Editorial Office Director
Return for Revision	2015-01-01 14:43
Revised	2015-05-13 00:00
Publication Fee Transferred
Second Decision by Editor	2015-05-29 15:18
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2015-06-08 15:51
Articles in Press	2015-06-08 16:25
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-07-23 15:09
Publish the Manuscript Online	2015-08-17 16:41

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Systematic Reviews
Article Title	Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer
Manuscript Source	Invited Manuscript
All Author List	Raji Shameem, Muhammad Saad Hamid, Kevin Y Xu and Shenhong Wu
Funding Agency and Grant Number
Corresponding Author	Shenhong Wu, MD, PhD, Associate Professor, Division of Hematology/Oncology, Department of Medicine, Stony Brook University School of Medicine, Stony Brook, NY 11794, United States. shenhong.wu@stonybrook.edu
Key Words	Abiraterone; Docetaxel; Metastatic castra­tion-resistant prostate cancer; Chemotherapy-naïve; Pre-chemotherapy; Post-chemotherapy
Core Tip	Our meta-analysis has demonstrated that pre-chemotherapy may affect the efficacy and toxicity of abiraterone treatment in patients with metastatic castration-resistant prostate cancer. Abiraterone was associated with significantly increased radiographic-progression-free survival, objective response rate, and prostate-specific antigen response rate in the pre-chemotherapy setting when compared to the post-chemotherapy setting. In addition, abiraterone in the pre-chemotherapy setting had a significant lower risk of all-grade fluid retention and edema (P < 0.001), and hypokalemia (P < 0.001), but had a higher risk of all-grade hypertension (P < 0.001) when compared to post-chemotherapy.
Publish Date	2015-08-17 16:41
Citation	Shameem R, Hamid MS, Xu KY, Wu S. Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer. World J Clin Oncol 2015; 6(4): 64-72
URL	http://www.wjgnet.com/2218-4333/full/v6/i4/64.htm
DOI	http://dx.doi.org/10.5306/wjco.v6.i4.64

Full Article (PDF)	WJCO-6-64.pdf
Full Article (Word)	WJCO-6-64.doc
Manuscript File	14825-Review.docx
Answering Reviewers	14825-Answering reviewers.pdf
Audio Core Tip	14825-Audio core tip.mp3
Biostatistics Review Certificate	14825-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	14825-Conflict-of-interest statement.pdf
Copyright License Agreement	14825-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	Editing_Certificate_20141026232202.docx
Peer-review Report	14825-Peer-review(s).pdf
Scientific Misconduct Check	14825-Scientific misconduct check.pdf
Scientific Editor Work List	14825-Scientific editor work list.pdf